Bile acids in glucose metabolism in health and disease
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
No Canadian affiliation. An affiliation-only frame — the usual design — would never have seen this work. It is one of the works that make the case for inverting the frame.
Machine scores (provisional)
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
- Teacher spread
- 0.332 · how far apart the two teachers sit on this one work
- Validation status
score_only:v0-immature-baseline· verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it
Abstract
Bile acids (BAs) are cholesterol-derived metabolites that facilitate the intestinal absorption and transport of dietary lipids. Recently, BAs also emerged as pivotal signaling molecules controlling glucose, lipid, and energy metabolism by binding to the nuclear hormone farnesoid X receptor (FXR) and Takeda G protein receptor 5 (TGR5) in multiple organs, leading to regulation of intestinal incretin secretion, hepatic gluconeogenesis, glycogen synthesis, energy expenditure, inflammation, and gut microbiome configuration. Alterations in BA metabolism and signaling are associated with obesity and type 2 diabetes mellitus (T2DM), whereas treatment of T2DM patients with BA sequestrants, or bariatric surgery in morbidly obese patients, results in a significant improvement in glycemic response that is associated with changes in the BA profile and signaling. Herein, we review the roles of BAs in glucose metabolism in health and disease; highlight the limitations, unknowns, and challenges in understanding the impact of BAs on the glycemic response; and discuss how this knowledge may be harnessed to develop innovative therapeutic approaches for the treatment of hyperglycemia and diabetes.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
The record
- Venue
- The Journal of Experimental Medicine
- Topic
- Drug Transport and Resistance Mechanisms
- Field
- Medicine
- Canadian institutions
- —
- Funders
- H2020 European Research CouncilConseil National de la Recherche ScientifiqueLeona M. and Harry B. Helmsley Charitable TrustCanadian Institute for Advanced ResearchIsrael Science FoundationGerman-Israeli Foundation for Scientific Research and DevelopmentBenoziyo Endowment Fund for the Advancement of ScienceEuropean Molecular Biology OrganizationBill and Melinda Gates FoundationMinerva FoundationEuropean Foundation for the Study of DiabetesHoward Hughes Medical Institute
- Keywords
- Farnesoid X receptorG protein-coupled bile acid receptorIncretinBile acidCarbohydrate metabolismGlycemicMicrobiomeLipid metabolismGluconeogenesisEndocrinologyInternal medicineDiabetes mellitusType 2 Diabetes MellitusMetabolismMedicineType 2 diabetesBiologyNuclear receptorBiochemistryBioinformatics
- Has abstract in OpenAlex
- yes